February / March #68 : Three-Way - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

A Daily Affirmation

Feed Your Head

TO: President George Bush

Puppet Masters

License to ddI

Longtime Companions: Tips For Two

You Sexy Thing

Indiana Jonesing

The Hanging CHAT

A Play In the Life

You Schmooze, You Lose

I Want My HIV

Speak Out

Once and Again


Redemption Song

Art from the Heart

S.O.S: Mouth Off

Zen at Work



Suck It Up

Comfort Zone

His M.O. is Her N-0

Sean's Trough Luck

Soul Survivors

Dyke Strike

A Rage to Age

Blood Brothers


02.16.90 Radiant Baby


Total Discord

Choosing Our Religion

Dogma & Devotion

The Brain Drain

Liver Lovers

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

February / March 2001


by Tim Horn

A trend among drug companies is to market already-approved anti-HIV drugs in adherence-friendlier formulations, a welcome advance (pardon the pun) for med-weary HIVers. On the heels of Combivir, Glaxo Wellcome's first combo (AZT and 3TC) comes Trizivir, which was approved last November and adds abacavir (Ziagen) to that mix. The one-pill-twice-daily triple-nuke regimen appears to be a good bet for those hoping to avoid more complicated cocktails containing PIs and non-nukes. But for some HIVers, it may be too good to be true.

Trizivir isn't a new drug. AZT and 3TC have long been the backbone of numerous drug regimens, and abacavir -- the most potent nuke -- was approved in late 1998. When all three drugs were studied together in a clinical trial, the result was a pleasant surprise for Glaxo: Its proprietary regimen was as effective as a PI-based regimen in reducing viral load among 562 first-time treatment takers.

But there's a catch: A closer look at the trial showed that the PI indinavir (Crixivan), combined with AZT and 3TC, was more effective than Trizivir in keeping the virus undetectable in folks with viral loads in the six-digit range. "Trizivir alone isn't a good choice for individuals with viral loads above 100,000 copies," says Paul Simmons, RN, ACRN, director of treatment education and advocacy at Houston's Center for AIDS. "But Trizivir -- or any of the drugs it contains -- can be used with PIs or non-nukes to maximize its benefits."

Upon approval, the FDA warned that Trizivir could be dangerous for HIVers allergic to abacavir, a potentially serious problem in 5 percent of takers. Fever and rash are two signs that the drug should be stopped. Also, anyone who's discontinued abacavir because of side effects shouldn't try Trizivir.

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.